Harnessing the tumor microenvironment: targeted cancer therapies through modulation of epithelial-mesenchymal transitionAntonino Glaviano, Alan Prem Kumar, Hannah Lau et al.|Journal of Hematology & Oncology|2025Cited by 128
A Single-cell Atlas Identifies Pretreatment Features of Primary Imatinib Resistance in Chronic Myeloid LeukemiaVaidehi Krishnan, S. Tiong Ong, Florian Schmidt et al.|Blood|2023Cited by 36
A Single-Cell Atlas Identifies Pretreatment Features of Primary Imatinib Resistance in Chronic Myeloid LeukemiaVaidehi Krishnan, S. Tiong Ong, Florian Schmidt et al.|Blood|2022Cited by 15
A phase 1b, multicentre, dose escalation, safety and pharmacokinetics study of tilvestamab (BGB149) in relapsed, platinum-resistant, high-grade serous ovarian cancer (PROC) patientsKenneth Sooi, David S.P. Tan, Sarah P. Blagden et al.|British Journal of Cancer|2025Cited by 2
PR070/#391 Phase I trial of tilvestamab, a function-blocking antibody inhibiting AXL, in platinum-resistant/refractory high grade serous ovarian cancer (PROC)David S.P. Tan, Line Bjørge, Tuan Zea Tan et al.|International Journal of Gynecological Cancer|2023Cited by 1